
Home » Xpovio Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Xpovio Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The FDA has granted accelerated approval to Karyopharm Therapeutics’ Xpovio (selinexor) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
The approval was based on the results of a phase 2 clinical trial in which Xpovio demonstrated an overall response rate of 29 percent.
Xpovio had been granted priority review and fast-track designations.
Upcoming Events
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar